10/ 573,090

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS 3 NOV 26 MARPAT enhanced with FSORT command
 NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
 NEWS 5 NOV 26 Two new SET commands increase convenience of STN
                  searching
 NEWS 6 DEC 01 ChemPort single article sales feature unavailable
 NEWS 7 DEC 12 GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
 NEWS 9 JAN 06 The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
 NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS   STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN   Welcome Banner and News Items
 NEWS IPC8   For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:01:43 ON 05 FEB 2009

=> file reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST   0.22   0.22

10/ 573,090

FILE 'REGISTRY' ENTERED AT 17:01:53 ON 05 FEB 2009

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2009 HIGHEST RN 1100909-82-7
DICTIONARY FILE UPDATES: 4 FEB 2009 HIGHEST RN 1100909-82-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573090.str



chain nodes :
11 18 20 21 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 22 23 24 25 26 27
chain bonds :
5-21 7-11 11-12 18-20 21-22 25-28 28-29 28-31 29-30 29-32
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :

10/ 573,090

5-21 7-11 11-12 18-20 21-22 25-28 28-31 29-30
exact bonds :
22-23 22-27 23-24 24-25 25-26 26-27 28-29 29-32
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
 15-16 16-17
isolated ring systems :
containing 1 : 12 : 22 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 17:02:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   9 TO ITERATE

100.0% PROCESSED   9 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

10/ 573,090

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:02:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 187 TO ITERATE

100.0% PROCESSED 187 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

L3 20 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 17:02:28 ON 05 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 4 Feb 2009 (20090204/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:260053 CAPLUS
DOCUMENT NUMBER: 142:336378

10/ 573,090

TITLE: Preparation of quinazoline derivatives as EGFR tyrosine kinase inhibitors
INVENTOR(S): Hennequin, Laurent Francois Andre; Halsall, Christopher Thomas
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026150	A1	20050324	WO 2004-GB3923	20040913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004272348	A1	20050324	AU 2004-272348	20040913
AU 2004272348	B2	20080904		
CA 2538884	A1	20050324	CA 2004-2538884	20040913
EP 1667991	A1	20060614	EP 2004-768469	20040913
EP 1667991	B1	20080514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014489	A	20061114	BR 2004-14489	20040913
CN 1882567	A	20061220	CN 2004-80033525	20040913
JP 2007505872	T	20070315	JP 2006-526682	20040913
AT 395346	T	20080515	AT 2004-768469	20040913
ES 2305844	T3	20081101	ES 2004-768469	20040913
MX 2006002964	A	20060614	MX 2006-2964	20060315
US 20070043009	A1	20070222	US 2006-573090	20060315
NO 2006001322	A	20060615	NO 2006-1322	20060323
KR 2007023631	A	20070228	KR 2006-707266	20060414
HK 1091480	A1	20080815	HK 2006-111949	20061031

PRIORITY APPLN. INFO.:
GB 2003-21620 A 20030916
GB 2004-6163 A 20040319
WO 2004-GB3923 W 20040913

OTHER SOURCE(S): CASREACT 142:336378; MARPAT 142:336378
GI



I



II

AB Title compds. I [R1 = H, OH, alkoxy, etc.; q = 1-5; each R2 independently = halo, CN, amino, nitro, etc.; Q1 = piperidinyl; p = 0-4; W independently = CF3, formyl, mercapto, etc.; X1 = CO, SO2; X2 = -(CR3R4)m-(Q2)n-(CR5R6)x-; m = 0-4; x = 0-4; n = 0-1; R3, R4, R5, R6 independently = H, alkyl, dialkylamino, etc.; Z = alkylamino, amino, OH, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as useful for the treatment of certain cancers. Thus, e.g., II was prepared by etherification of 4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-ol (preparation given) with tert-butyl-(4-methanesulfonyloxy)piperidine-1-carboxylate followed by deesterification and acetylation with N,N-dimethylaminoacetyl chloride. The activity of I was evaluated in different inhibition assays directed at inhibiting phosphorylation, cell proliferation, and in vivo tumor growth and revealed that all compds. of the invention possessed IC50 values of 0.001-5 μM or activity in the range of 1-200 mg/kg/day. I as tyrosine kinase inhibitors should prove useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

IT 848439-61-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as inhibitors of EGFR tyrosine kinase)

RN 848439-61-2 CAPLUS

CN 1-Propanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 848439-62-3P 848439-67-8P 848439-70-3P
848439-78-1P 848439-87-2P 848439-88-3P
848439-90-7P 848439-91-8P 848439-92-9P
848439-93-0P 848439-94-1P 848439-95-2P
848439-96-3P 848439-97-4P 848439-98-5P
848439-99-6P 848440-00-6P 848440-01-7P
848440-02-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as inhibitors of EGFR tyrosine kinase)

RN 848439-62-3 CAPLUS

CN 1-Pentanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-3-methyl-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-67-8 CAPLUS

CN 1-Butanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-70-3 CAPLUS
CN 1-Butanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-3,3-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-78-1 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-87-2 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-[2-(1-pyrrolidinyl)ethoxy]-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-88-3 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-(2-methoxyethoxy)-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-90-7 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-2-fluorophenyl)amino]-6-(1-methylethoxy)-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-91-8 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-92-9 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-93-0 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-bromophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-94-1 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-bromophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-95-2 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(5-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-96-3 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(5-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-97-4 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-ethynylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-98-5 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-ethynylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848439-99-6 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848440-00-6 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(3-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848440-01-7 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848440-02-8 CAPLUS
CN 1-Propanone, 1-[4-[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:01:43 ON 05 FEB 2009)

FILE 'REGISTRY' ENTERED AT 17:01:53 ON 05 FEB 2009
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 20 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:02:28 ON 05 FEB 2009
L4 1 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	XXXXXXXXXXXXXXXX	

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-0.82

STN INTERNATIONAL LOGOFF AT 17:02:52 ON 05 FEB 2009

10/ 573,090